US 10,889,640 B2
Tau-binding antibodies
David Edward Ormonde Knight, Slough (GB); Terence Seward Baker, Slough (GB); David James McMillan, Slough (GB); Robert Anthony Griffin, Slough (GB); Georges Mairet-Coello, Brussels (BE); Patrick Downey, Brussels (BE); and Jean-Philippe Courade, Brussels (BE)
Assigned to UCB BIOPHARMA SPRL, Brussels (BE)
Filed by UCB BIOPHARMA SPRL, Brussels (BE)
Filed on May 13, 2019, as Appl. No. 16/409,945.
Application 16/409,945 is a continuation of application No. 15/742,087, granted, now 10,287,343, previously published as PCT/EP2016/065813, filed on Jul. 5, 2016.
Claims priority of application No. 15175522 (EP), filed on Jul. 6, 2015.
Prior Publication US 2019/0284267 A1, Sep. 19, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C07K 14/47 (2006.01); A61P 25/28 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); C07K 14/4711 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 10 Claims
OG exemplary drawing
 
3. An isolated nucleic acid comprising SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 26, 56 or 57.